AU2003297689A1 - Multilayered tablet containing pravastatin and aspirin - Google Patents

Multilayered tablet containing pravastatin and aspirin

Info

Publication number
AU2003297689A1
AU2003297689A1 AU2003297689A AU2003297689A AU2003297689A1 AU 2003297689 A1 AU2003297689 A1 AU 2003297689A1 AU 2003297689 A AU2003297689 A AU 2003297689A AU 2003297689 A AU2003297689 A AU 2003297689A AU 2003297689 A1 AU2003297689 A1 AU 2003297689A1
Authority
AU
Australia
Prior art keywords
aspirin
pravastatin
layer containing
tablet containing
multilayered tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003297689A
Other languages
English (en)
Other versions
AU2003297689A8 (en
Inventor
Loutfy Benkerrour
Olivier Galley
Francoise Quinet
Peter Timmins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32505946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003297689(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2003297689A8 publication Critical patent/AU2003297689A8/xx
Publication of AU2003297689A1 publication Critical patent/AU2003297689A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003297689A 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin Abandoned AU2003297689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method
US10/316,424 2002-12-11
PCT/US2003/038774 WO2004052289A2 (en) 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin

Publications (2)

Publication Number Publication Date
AU2003297689A8 AU2003297689A8 (en) 2004-06-30
AU2003297689A1 true AU2003297689A1 (en) 2004-06-30

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003297689A Abandoned AU2003297689A1 (en) 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin

Country Status (17)

Country Link
US (1) US20040115265A1 (enExample)
EP (1) EP1581194B1 (enExample)
JP (1) JP2006511520A (enExample)
AT (1) ATE401061T1 (enExample)
AU (1) AU2003297689A1 (enExample)
CY (1) CY1108414T1 (enExample)
DE (1) DE60322264D1 (enExample)
DK (1) DK1581194T3 (enExample)
ES (1) ES2308040T3 (enExample)
IS (1) IS2877B (enExample)
MY (1) MY140947A (enExample)
NO (1) NO338696B1 (enExample)
PL (1) PL206190B1 (enExample)
PT (1) PT1581194E (enExample)
SI (1) SI1581194T1 (enExample)
TW (1) TWI361700B (enExample)
WO (1) WO2004052289A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
WO2007027566A2 (en) * 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) * 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
KR101330096B1 (ko) * 2007-10-12 2013-11-15 페링 인터내셔널 센터 에스 에이 구연산, 산화 마그네슘, 중탄산칼륨 및 피코황산나트륨을 포함하는 의약품의 제조 방법, 이러한 방법에 의해 제조된 과립을 포함하는 약제학적 조성물 및 중간체
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
JP5905031B2 (ja) * 2011-01-28 2016-04-20 インタッチ テクノロジーズ インコーポレイテッド モバイルテレプレゼンスロボットとのインタフェーシング
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
JP7109748B2 (ja) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
EP1581194B1 (en) 2008-07-16
TW200505432A (en) 2005-02-16
CY1108414T1 (el) 2014-02-12
WO2004052289A3 (en) 2005-03-24
IS7889A (is) 2005-06-10
NO20052734D0 (no) 2005-06-07
DE60322264D1 (de) 2008-08-28
US20040115265A1 (en) 2004-06-17
PL377265A1 (pl) 2006-01-23
ES2308040T3 (es) 2008-12-01
NO338696B1 (no) 2016-10-03
TWI361700B (en) 2012-04-11
AU2003297689A8 (en) 2004-06-30
EP1581194A4 (en) 2006-03-15
ATE401061T1 (de) 2008-08-15
PL206190B1 (pl) 2010-07-30
DK1581194T3 (da) 2008-10-20
EP1581194A2 (en) 2005-10-05
WO2004052289A2 (en) 2004-06-24
JP2006511520A (ja) 2006-04-06
SI1581194T1 (sl) 2008-12-31
NO20052734L (no) 2005-07-07
MY140947A (en) 2010-02-12
PT1581194E (pt) 2008-09-24
IS2877B (is) 2014-04-15

Similar Documents

Publication Publication Date Title
MY140947A (en) Multilayered tablet containing pravastatin and aspirin and method
AU2003236831A1 (en) Materials containing multiple layers of vesicles
AU2003251642A1 (en) Laser markable carrier unit
AU2003303377A1 (en) Vapor deposited titanium and titanium-nitride layers for dental devices
WO2007001337A3 (en) Coated substrates and methods for their preparation
AU2002365423A1 (en) Methods and reactors for forming superconductor layers
PE20000349A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina
AU2002313652A1 (en) Fast swap dual substrate transport for load lock
HUP0100406A2 (hu) Egy vagy több hatóanyag azonnali és tartós felszabadulását biztosító tabletta
AU2003234610A1 (en) Higher layer bonding of multiple access lines for carrier grade access
AU2002309511A1 (en) Seabed oil storage and tanker offtake system
AU9629198A (en) Monolithic system containing one or more drugs, consisting of three layers with different release mechanisms
AU2003282156A1 (en) Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes
AU2003244210A1 (en) Reduced-reflection film having low-refractive-index layer
AU2003274215A1 (en) Prestressable layer system for partition glass
AU2003288617A1 (en) Method for sharing contents using the webdvd technology
AU2003285237A1 (en) Barrier layer for thick film dielectric electroluminescent displays
AU2003255450A1 (en) Polyolefin multilayered film, method for the production of said film and use thereof
AU2003268785A1 (en) Stabilized aluminum laminate having aluminum and stabilizing layer laminated thereon
AU2002311744A1 (en) Authoring platform for synchronized multimedia presentation
Sowers Stroke in patients with diabetes
AU2003283784A1 (en) Rewritable optical record carrier
WO2005081651A3 (en) Housebuilding, wall element and method related thereto
AU2003285653A1 (en) Dual layer birefringent optical component
AU2002227815A1 (en) Insertion layer for thick film electroluminescent displays

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 30, PAGE(S) 8014 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME BRISTOL-MYERS SQUIBB COMPANY, APPLICATION NO. 2003297689, UNDER INID (71) CORRECT THE NAME TO READ BRISTOL-MYERS SQUIBB COMPANY; ABEBE, ADMASSU